Matches in Nanopublications for { ?s ?p "[Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion description "[Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217013.RA7MsBnP4K-Kc2xFQjIJPzf5pgKqPQlISIwUYCIp5cMN8130_assertion description "[Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217013.RA7MsBnP4K-Kc2xFQjIJPzf5pgKqPQlISIwUYCIp5cMN8130_provenance.